With eye on revenue stabilization, Gilead takes 4.9% hike on a basket of drugs
Once the hep C titan, Gilead is now fortifying its still dominant HIV business with a round of list price hikes it took over the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
